Mandibular advancement device therapy in obstructive sleep apnea
Aarab, G.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Chapter 5

Oral appliance therapy versus nasal continuous positive airway pressure in obstructive sleep apnea: a randomized, placebo-controlled trial

Ghizlane Aarab, Frank Lobbezoo, Hans L. Hamburger, Machiel Naeije

Respiration 2011; 81: 411-419
Abstract

**Background:** Previous randomized controlled trials have addressed the efficacy of mandibular advancement devices (MADs) in the treatment of obstructive sleep apnea (OSA). Their common control condition, (nasal) continuous positive airway pressure (nCPAP), was frequently found to be superior to MAD therapy. However, in most of these studies, only nCPAP was titrated objectively, but not MAD. To enable an unbiased comparison between both treatment modalities, the MAD should be titrated objectively as well. **Objective:** The aim of the present study was to compare the treatment effects of a titrated MAD with those of nCPAP and an intra-oral placebo device. **Methods:** Sixty-four mild/ moderate OSA patients (52.0 ± 9.6 years) were randomly assigned to three parallel groups: MAD, nCPAP, and placebo device. From all patients, two polysomnographic (PSG) recordings were obtained at the hospital: one before treatment and one after approximately six months of treatment. **Results:** The change in the apnea-hypopnea index (ΔAHI) between baseline and therapy evaluation differed significantly between the three therapy groups (ANCOVA; \( P = 0.000 \)). No differences in the ΔAHI were found between the MAD and nCPAP therapy (\( P = 0.092 \)), whereas the changes in AHI in these groups were significantly larger than those in the placebo group (\( P = 0.000 \) and 0.002, respectively). **Conclusion:** There is no clinically relevant difference between MAD and nCPAP in the treatment of mild to moderate OSA when both treatment modalities are titrated objectively. **Key words:** mandibular advancement device · continuous positive airway pressure · placebo · randomized controlled trial · obstructive sleep apnea · therapy · treatment

Introduction

Obstructive sleep apnea (OSA) is defined as a recurrent obstruction of the upper airway, often resulting in oxygen desaturation and arousal from sleep [1]. OSA is a common disorder in the general middle-aged population, affecting approx. 2% of women and 4% of men [2]. As reviewed extensively, OSA patients can suffer from a range of consequences of their condition, including not only complaints of snoring and excessive daytime sleepiness but also symptoms of neurocognitive impairment and mood disturbance [2, 3]. Further, they may develop cardiovascular problems, like myocardial infarction and stroke. Since these symptoms and problems have a great impact on an OSA patient’s quality of life and life expectancy, adequate treatment is indicated.

Treatment options for OSA include, amongst others, behavioural modification (e.g., weight loss and alteration of sleep posture) and continuous positive airway pressure (CPAP), while particularly over the past decade mandibular advancement devices (MADs) are increasingly used [3-5]. During sleep, these devices advance the mandible and/or the tongue, thereby increasing the size of the upper airway. Various randomized controlled trials have addressed the efficacy of MADs in the treatment of OSA [6-12]. Their common control condition, CPAP, was found to be superior to MAD therapy. However, in most of these studies, CPAP was titrated objectively (i.e., by using polysomnography, PSG), but not the MAD. To enable an unbiased comparison between both treatment modalities, the MAD should be titrated objectively as well.

Therefore, the aim of the present study was to compare the effects of an MAD with those of nasal CPAP (nCPAP) following PSG controlled titration of both treatment modalities. The hypothesis for this study was that MAD is as effective as nCPAP in the treatment of mild/ moderate OSA. To control for possible placebo effects in subjective outcome variables like excessive daytime sleepiness and health perception, an intra-oral placebo device served as passive control condition for both active treatment modalities. The study was performed according to the CONSORT (consolidated standards of reporting trials) statement [13], employing a parallel-group, randomized, placebo-controlled trial design.
Methods

Setting and participants

Eligible OSA patients, living in the greater Amsterdam area, were referred to the Slotervaart Medical Center by their family physician. All patients underwent a thorough medical examination, including a full PSG recording, at the departments of Neurology, Pulmonary Medicine, and ENT, as well as a thorough dental examination at the Department of Oral Kinesiology of ACTA. OSA patients were invited for participation in this study when they fulfilled the following inclusion criteria: age > 18 years, an apnea-hypopnea index (AHI) between 5 and 45 events per hour, and a report of excessive daytime sleepiness (Epworth Sleepiness Score ≥ 10) or at least two of the symptoms suggested by the American Academy of Sleep Medicine Task Force, e.g., unrefreshing sleep and daytime fatigue [1, 14]. The medical and dental exclusion criteria are shown in Table 1. Exclusion of temporomandibular disorders was based on a functional examination of the masticatory system [15, 16].

The scientific and ethical aspects of this study’s protocol were approved by the Medical Ethics Committee of the Slotervaart Medical Center (# U/1731/0326, U/2679/0326).

Randomisation and allocation

After written informed consent was obtained, the patients were randomly allocated to one of three therapy groups (MAD, nCPAP, or placebo). To ensure that the groups were of approximately the same size, block randomisation was used. Block sizes were 6, 12, and 18; sizes were randomly varied. The allocation sequence was automatically generated and subsequently concealed by an independent co-worker, who kept a paper copy in a lockable drawer. Sealed opaque envelopes were used to conceal the allocation from the principal investigator.

Interventions and blinding

Three forms of therapy interventions were used in this parallel-group study. First, an individually fabricated MAD with an adjustable protrusive mandibular position at a constant vertical dimension was used [17, 18]. Second, nCPAP of the REMstar Pro system was used (Respironics, Herrsching, Germany). Third, a thin (< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used as a placebo [19].

<table>
<thead>
<tr>
<th>Table 1 Number of patients excluded based on the medical and dental exclusion criteria used in this study.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusion criteria</strong></td>
</tr>
<tr>
<td>Medical</td>
</tr>
<tr>
<td>Respiratory/sleep disorder other than OSA</td>
</tr>
<tr>
<td>Body Mass Index &gt; 40</td>
</tr>
<tr>
<td>Medication usage that could influence respiration or sleep</td>
</tr>
<tr>
<td>Periodic Limb Movement Disorder</td>
</tr>
<tr>
<td>Previous treatment with CPAP or MAD</td>
</tr>
<tr>
<td>Reversible morphological upper airway abnormalities (e.g., enlarged tonsils)</td>
</tr>
<tr>
<td>Other medical conditions (e.g., psychiatric disorder)</td>
</tr>
<tr>
<td>Dental</td>
</tr>
<tr>
<td>Temporomandibular disorders</td>
</tr>
<tr>
<td>Untreated periodontal problems</td>
</tr>
<tr>
<td>Dental pain</td>
</tr>
<tr>
<td>Lack of retention possibilities for an oral appliance</td>
</tr>
</tbody>
</table>
Patients were blinded to the nature of the assigned therapy (placebo or active). After evaluating the therapy, all patients were asked if they were of the opinion that they had received an active or placebo treatment. As indicated below, blinding of the analyst was ascertained by assigning codes to data sets and by analyzing these sets in random blocks.

Procedure

From all patients, two full PSG recordings were obtained in the sleep laboratory of the Slotervaart Medical Center, using Siesta hardware and Pro-Fusion software (Compumedics, Abbotsford, Australia): one before therapy assignment (baseline PSG) and one after 6 ± 2 months (mean ± SD) of treatment (therapy evaluation PSG). The primary and secondary outcome measures were obtained at baseline and therapy evaluation.

The MAD and nCPAP were titrated before the start of the treatment. The titration of the nCPAP was performed during a third sleep laboratory examination. The pressure was increased in incremental steps of 1 cm H2O/h, until respiratory disturbances and respiration-related arousals were reduced to ≤ 5/h, and snoring was minimized. The average value of the pressure was 7.3 (SD, 1.9; range, 4-11) cm H2O.

For the titration of the MAD, four ambulatory PSG recordings were obtained at regular intervals [18], using Monet hardware and Rembrandt Software (Medcare Automation B.V., Amsterdam, The Netherlands). The most effective protrusion position of the MAD (i.e., the mandibular position that yielded the lowest AHI value) was chosen from among four randomly offered positions (viz., 0%, 25%, 50%, and 75% of the maximum protrusion). The MAD was set at 25% of the maximum protrusion in one patient, at 50% in 7 patients, and at 75% in 12 patients.

For the placebo group, the study procedure was made equally intense as that for the MAD group by making four ambulatory PSG recordings at regular intervals as well.

For all patients, the therapy evaluation PSG recordings were followed by a visit at ACTA, during which the patients were interviewed about (1) their compliance (% of nights per week usage), (2) the change in snoring sound (disappeared, decreased, remained unchanged, or increased) as reported by a partner, and (3) side effects (nature and number) of the patients’ therapy.

Outcome measures

The change in the apnea-hypopnea index (ΔAHI) between baseline and therapy evaluation was the primary outcome variable. Secondary outcome variables were the changes in other respiratory and sleep variables, in excessive daytime sleepiness, and in health perception (short-form General Health Survey, SF-36) [20] between baseline and therapy evaluation. Other secondary outcome variables were self-reported compliance, snoring, and side-effects.

Data analysis

An effect size of 0.8 standard deviation (SD) between two treatments is generally considered to be large [21] and should therefore not be overlooked. A sample size of 20 patients per intervention group was calculated to detect this effect size with a power of 80% and a significance level of 5% (two-sided). Accordingly, it was decided to include 20 patients in each intervention group.

The patient characteristics at baseline of the three therapy groups were analyzed using one-way analyses of variance, followed by least-significant difference (LSD) pair-wise comparisons. Patient characteristics that were significantly different between the three groups were used as covariate in the per-protocol analyses and in the intention-to-treat analyses (see below).

The per-protocol analyses included only those patients who completed the trial. Except for compliance, snoring reports, and side effects, which were analyzed differently (see below), ANCOVAs were used to detect differences in therapy effect between the three groups for both the primary and the secondary outcome variables. For each variable, its baseline value was used as covariate. In the three sets of secondary outcome variables (viz., respiratory variables other than AHI, sleep, and SF-36), the Bonferroni-Holm correction was
used to correct for multiple comparisons [22]. For the primary and secondary outcome variables that thus showed a significant therapy effect between the groups, simple contrast analyses were performed. Further, the effect size (including the 95% confidence interval, CI) of the primary outcome variable between MAD and nCPAP was calculated, after correcting the ΔAHIs for the influence of baseline. According to the guidelines by Cohen [21], an effect size of 0.2 is small, of 0.5 is medium, and of 0.8 is large.

ANOVA was used to detect differences in compliance between the three therapy groups. To evaluate the association between self-reported snoring and the three groups, a chi-square test was conducted. Finally, the nature and number of side-effects were described and counted.

In an intention-to-treat analysis, the effect of missing ΔAHI values was tested in a series of sensitivity analyses following the suggestion by Petri et al. [23]. In the worst-case scenario, a failure pattern was chosen for the missing ΔAHI values of the MAD group, and a success pattern for the nCPAP and placebo groups. In the best-case scenario, a success pattern was chosen for the missing ΔAHI values of the MAD group and a failure pattern for the nCPAP and placebo group. The failure pattern was defined as the missing ΔAHI value being equal to the smallest value in the group of interest; the success pattern as the missing ΔAHI value being equal to the largest value in the group of interest. In case that the AHI value at therapy evaluation would then become negative, the ΔAHI was chosen such that the AHI at therapy evaluation was equal to zero. One-way analysis of covariance (ANCOVA), using the baseline value of AHI as covariate, and simple contrast analyses were used to detect differences in therapy effect in the worst-case and in the best-case scenario.

Statistical tests were performed with the SPSS 15.0 software package (SPSS Inc., Chicago, IL).

Results

Figure 1 shows a flow-chart for the 219 patients who were eligible for the study. Seventy-three patients were excluded for medical reasons; 29 patients, for dental reasons (Table 1). Thirty-one patients refused to participate and 22 patients did not participate for various other reasons, e.g., loss of contact. Finally, 64 patients enrolled into the study and 57 patients completed the study.

The patient characteristics at baseline are presented in Table 2. BMI was the only baseline characteristic that differed between the three therapy groups (F = 5.170; P = 0.008). LSD analyses revealed that the MAD group had a significantly lower BMI than the placebo and nCPAP groups (P = 0.002 and 0.006, respectively). Therefore, BMI was entered as covariate in the below-described analyses of covariance. Within the three treatment groups, the BMI showed no change from baseline to therapy evaluation (paired T-tests; P = 0.408 - 0.752).

The mean baseline values (± SD) of the respiratory and sleep variables as well as the changes in these variables from baseline to therapy evaluation are shown in Table 3.
Fig. 1. Flow-chart of the patients through each stage of the trial. MAD = mandibular advancement device; nCPAP = nasal continuous positive airway pressure.

Table 2 Patient characteristics at baseline of the mandibular advancement device (MAD) group, nasal continuous positive airway pressure (nCPAP) group, placebo group, and drop-outs.

<table>
<thead>
<tr>
<th></th>
<th>MAD (n = 20)</th>
<th>nCPAP (n = 18)</th>
<th>Placebo (n = 19)</th>
<th>Drop-outs (n = 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>50.3 ± 9.1</td>
<td>55.4 ± 9.8</td>
<td>51.3 ± 10.1</td>
<td>49.3 ± 7.3</td>
</tr>
<tr>
<td><strong>Number of man/woman</strong></td>
<td>16/4</td>
<td>12/6</td>
<td>14/5</td>
<td>5/2</td>
</tr>
<tr>
<td><strong>Apnea-hypopnea index</strong></td>
<td>22.1 ± 10.8</td>
<td>20.9 ± 9.8</td>
<td>20.1 ± 8.7</td>
<td>14.8 ± 3.8</td>
</tr>
<tr>
<td><strong>Body Mass Index (kg/m²)</strong></td>
<td>27.1 ± 3.2</td>
<td>30.7 ± 3.7</td>
<td>31.1 ± 4.7</td>
<td>27.8 ± 4.1</td>
</tr>
<tr>
<td><strong>Neck circumference (cm)</strong></td>
<td>41.7 ± 3.0</td>
<td>43.6 ± 4.0</td>
<td>42.6 ± 3.2</td>
<td>41.4 ± 4.8</td>
</tr>
<tr>
<td><strong>Epworth sleepiness score</strong></td>
<td>11.8 ± 5.8</td>
<td>10.2 ± 4.7</td>
<td>10.6 ± 4.1</td>
<td>13.7 ± 1.9</td>
</tr>
<tr>
<td><strong>36-item short-form health survey</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical functioning</td>
<td>82.9 ± 22.7</td>
<td>61.1 ± 24.8</td>
<td>77.4 ± 24.2</td>
<td>73.8 ± 18.4</td>
</tr>
<tr>
<td>Social functioning</td>
<td>75.0 ± 23.6</td>
<td>64.8 ± 25.5</td>
<td>75.7 ± 29.0</td>
<td>77.5 ± 22.3</td>
</tr>
<tr>
<td>Role physical</td>
<td>53.9 ± 48.1</td>
<td>64.7 ± 45.1</td>
<td>69.7 ± 39.6</td>
<td>45.0 ± 51.2</td>
</tr>
<tr>
<td>Role emotional</td>
<td>77.2 ± 41.7</td>
<td>76.5 ± 40.4</td>
<td>78.9 ± 37.2</td>
<td>73.3 ± 43.5</td>
</tr>
<tr>
<td>Mental health</td>
<td>66.7 ± 14.1</td>
<td>64.5 ± 22.7</td>
<td>69.9 ± 21.9</td>
<td>69.6 ± 19.3</td>
</tr>
<tr>
<td>Vitality</td>
<td>49.7 ± 18.0</td>
<td>46.3 ± 19.5</td>
<td>48.7 ± 26.1</td>
<td>56.0 ± 12.9</td>
</tr>
<tr>
<td>Bodily pain</td>
<td>79.6 ± 27.9</td>
<td>65.9 ± 28.8</td>
<td>82.1 ± 26.2</td>
<td>71.0 ± 35.4</td>
</tr>
<tr>
<td>General health perception</td>
<td>54.7 ± 22.3</td>
<td>49.6 ± 16.5</td>
<td>60.3 ± 21.3</td>
<td>52.0 ± 8.4</td>
</tr>
<tr>
<td>Health transition</td>
<td>41.3 ± 24.7</td>
<td>38.3 ± 29.7</td>
<td>45.8 ± 21.4</td>
<td>50.0 ± 17.7</td>
</tr>
</tbody>
</table>

*MAD patients had a significantly lower BMI than placebo and nCPAP patients (P = 0.002 and 0.006, respectively).
Table 3: The mean (± SD) baseline and delta (i.e., difference between baseline and therapy evaluation) values of the respiratory and sleep outcome variables of the three groups (MAD, nCPAP, and Placebo).

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Δ value</th>
<th>Baseline</th>
<th>Δ value</th>
<th>Baseline</th>
<th>Δ value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Respiration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AHI (events/hour)</td>
<td>22.1 ± 10.8</td>
<td>16.3 ± 10.3</td>
<td>20.9 ± 9.8</td>
<td>19.5 ± 8.7</td>
<td>20.1 ± 8.7</td>
<td>5.2 ± 10.5</td>
</tr>
<tr>
<td>AHI_REM_supine (events/hour)</td>
<td>24.6 ± 31.5</td>
<td>12.5 ± 34.8</td>
<td>31.2 ± 30.5</td>
<td>26.7 ± 30.4</td>
<td>32.2 ± 28.1</td>
<td>5.6 ± 31.1</td>
</tr>
<tr>
<td>AHI_NREM_supine (events/hour)</td>
<td>33.0 ± 23.9</td>
<td>25.1 ± 21.4</td>
<td>39.2 ± 25.9</td>
<td>34.0 ± 24.4</td>
<td>22.1 ± 16.4</td>
<td>-2.6 ± 23.1</td>
</tr>
<tr>
<td>AHI_REM_non-supine (events/hour)</td>
<td>15.1 ± 14.9</td>
<td>7.5 ± 13.0</td>
<td>16.4 ± 16.5</td>
<td>14.1 ± 21.3</td>
<td>15.1 ± 15.7</td>
<td>4.4 ± 21.5</td>
</tr>
<tr>
<td>AHI_NREM_non-supine (events/hour)</td>
<td>11.3 ± 11.9</td>
<td>8.6 ± 10.8</td>
<td>10.2 ± 9.8</td>
<td>8.9 ± 9.4</td>
<td>12.6 ± 12.1</td>
<td>5.9 ± 9.0</td>
</tr>
<tr>
<td><strong>Sleep</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total sleep time (min)</td>
<td>425.0 ± 128.6</td>
<td>-11.8 ± 143.2</td>
<td>473.8 ± 83.2</td>
<td>58.8 ± 101.2</td>
<td>444.2 ± 82.9</td>
<td>-7.8 ± 113.4</td>
</tr>
<tr>
<td>Stage 1 and 2 (%)</td>
<td>68.8 ± 10.8</td>
<td>8.2 ± 14.7</td>
<td>67.0 ± 8.5</td>
<td>0.8 ± 9.1</td>
<td>66.2 ± 11.9</td>
<td>0.8 ± 11.8</td>
</tr>
<tr>
<td>Stage 3 and 4 (%)</td>
<td>14.5 ± 10.9</td>
<td>-3.1 ± 9.6</td>
<td>12.9 ± 8.4</td>
<td>-1.4 ± 8.7</td>
<td>14.1 ± 7.9</td>
<td>-0.1 ± 9.4</td>
</tr>
<tr>
<td>Stage REM (%)</td>
<td>18.3 ± 6.4</td>
<td>-1.9 ± 6.4</td>
<td>20.0 ± 6.4</td>
<td>0.6 ± 8.2</td>
<td>19.7 ± 6.7</td>
<td>-0.7 ± 6.1</td>
</tr>
<tr>
<td>Sleep in supine position (%)</td>
<td>47.4 ± 26.3</td>
<td>7.7 ± 32.9</td>
<td>38.5 ± 22.2</td>
<td>-10.1 ± 30.3</td>
<td>39.5 ± 25.3</td>
<td>5.8 ± 38.7</td>
</tr>
<tr>
<td>Respiratory arousal index (events/hour)</td>
<td>17.0 ± 9.6</td>
<td>13.0 ± 9.0</td>
<td>16.4 ± 8.9</td>
<td>13.9 ± 11.8</td>
<td>13.8 ± 6.6</td>
<td>3.5 ± 8.2</td>
</tr>
</tbody>
</table>

Definition of abbreviations: AHI = apnea-hypopnea index, REM = rapid-eye-movement, NREM = non-rapid-eye-movement. Δ value = difference between baseline and therapy evaluation values.

* P-value as result of the ANCOVA comparing the three groups, controlled for the effect of the baseline value and BMI.
† Statistically significant at the 0.05 probability level.
‡ Statistically significant after Bonferroni-Holm correction.

In the per-protocol analysis, the three groups showed significant differences in the changes in AHI from baseline to therapy evaluation (F = 14.886, P = 0.000; see Table 3 and Figure 2). No differences in primary outcome variable (f = 14.886, P = 0.000; see Table 3 and Figure 2). No differences in the AHI, whereas the changes in the MAD and nCPAP therapy groups were significantly larger than those in the placebo group (P = 0.000 and 0.002, respectively). The effect size between MAD and nCPAP was significantly smaller than that in the MAD group. The reduction in the nCPAP group being larger than that in the MAD group. The best-case scenario showed similar results as the per-protocol analyses.

Also in the intention-to-treat analysis, the three groups differed significantly in their change in AHI (Worst-case: F = 14.890, P = 0.000). In the worst-case scenario, the MAD group showed a small but significant reduction in AHI between baseline and therapy evaluation (paired T-test; P = 0.044). Also in the intention-to-treat analysis, the three groups differed significantly in their change in AHI (Worst-case: F = 14.890, P = 0.000). In the worst-case scenario, the MAD group showed a small but significant reduction in AHI between baseline and therapy evaluation (paired T-test; P = 0.044).
Secondary outcome variables

Respiration – In the non-supine position, no significant differences were found in the changes in secondary respiratory variables between the three groups. However, in the supine position, the nCPAP group showed larger reductions in AHI in the REM and NREM sleep than the placebo group (P = 0.000), while the MAD group showed only a larger reduction in AHI during the NREM sleep (P = 0.001).

Sleep – Of the sleep variables analysed, only the changes in respiratory arousal index were different between the three therapy groups (Table 3). The MAD and nCPAP groups showed significantly larger reductions than the placebo group (P = 0.032 and 0.003, respectively).

Questionnaires – The changes in excessive daytime sleepiness between baseline and therapy evaluation were not different between the three groups (F = 0.070; P = 0.933). The pooled data of the three groups showed a significant decrease with treatment (paired T-test, P = 0.002). Within the pooled data of the MAD and nCPAP group, and also within the placebo group, the improvements in excessive daytime sleepiness were also significant (P = 0.037 and 0.012, respectively). The changes in the domains of the SF-36 were not significantly different between the three groups (F = 1.518, P = 0.228). In the MAD and nCPAP group, none of the patients were of the opinion that they had received a placebo treatment. On the other hand, 5 of the 19 patients of the placebo group were convinced that they had received a placebo treatment.

Snoring – None of the patients reported an increase in snoring. Changes in snoring differed significantly between the three therapy groups (X2 = 32.069, P = 0.000). Snoring had decreased more frequently in the MAD group and had disappeared more frequently in the nCPAP group. The placebo group more frequently reported no change in snoring.

Side-effects - The MAD group reported the following side-effects: sensitive teeth upon awakening (n = 9), tenderness in the masseter muscle region upon awakening (n = 13), discomfort in wearing (n = 10), hypersalivation (n = 9), dry mouth (n = 4), feeling of a changed occlusion upon awakening (n = 9), and difficulty swallowing with the MAD in situ (n = 3). The following side-effects were reported by the nCPAP group: dry mouth (n = 3), problems with expiration against the positive pressure (n = 5), pain due to pressure of the mask (n = 6), nasal congestion (n = 2), air leaks due to the mask (n = 2), conjunctivitis (n = 2), and difficulty in changing sleep position (n = 3). In the placebo group, no side-effects were reported.

Discussion

The aim of this randomized, placebo-controlled trial was to compare the effects of an MAD with those of nasal CPAP (nCPAP) following PSG controlled titration of both treatment modalities.

Previous RCTs have also addressed the efficacy of MADs in the treatment of OSA [6-12, 24]. In these studies, the MAD was set in a fixed protrusion position [8,11, 12], or the MAD was titrated by the patients themselves or by their dentist. This titration was then based on the patient’s subjective evaluation of improvement [6, 10, 24]. However, it can be questioned whether this titration method will yield the most effective mandibular position (i.e., the position that leads to the lowest values of the AHI). As to enable an unbiased comparison between MAD and nCPAP, the MAD has to be titrated as objectively as possible. Therefore, in this study, four ambulatory PSG recordings were made for each MAD patient, with the MAD set at four different positions. This method had as disadvantage that four full-night recordings had to be made. A recent study suggests that this disadvantage may be overcome by using a one-night MAD titration procedure [9].
Mandibular Advancement Device Therapy in Obstructive Sleep Apnea

In the per-protocol analysis, no significant difference between MAD and nCPAP was found in the improvement of AHI. In the worst-case scenario, with the failure and success patterns set at their extreme values in favour of nCPAP, the difference between the two treatment modalities was significant ($P = 0.043$). No difference in treatment results between MAD and nCPAP has been found in a previous trial by Tan et al. [24]. On the other hand, better treatment results for CPAP are also reported [6-12]. Differences in results may be due to differences in study design, in the way the MAD was titrated, in the baseline characteristics of the study participants (e.g., the severity of the OSA-condition), in the primary outcome variable chosen, or in the specifics of the appliances and devices used.

Figure 2 shows that two patients in the MAD group did not respond at all to the treatment given. As not all patients are able to achieve a successful outcome when treated with an MAD, the development of methods to assist in the selection of who will respond to treatment would be of significant importance. Previous studies have identified a range of anthropomorphic, physiologic, and polysomnographic variables associated with a better treatment outcome [25-28]. However, more research is needed to improve the prediction of the treatment outcome of an MAD [5].

Another way of looking at treatment results is not by evaluating the changes in AHI, but by focusing at the treatment outcome values themselves. A cut-off point of 5 for the AHI is often used, not only to recognize the presence of OSA, but also to define an OSA treatment to be successful or not [29, 30]. Unfortunately, OSA has a strong time-variant nature, and this complicates the use of a single cut-off point. An AHI value of 9.8, obtained from a single night recording, is at the threshold of the 95% probability band around the cut-off point of 5 [31]. Therefore, Aarab et al. [31] recommended using this value in the recognition of OSA. Taking this recommendation into account, 85% of the MAD group, and 100% of the nCPAP group were treated successfully. In considering the clinical relevance of a difference between a new treatment (in this case MAD) and a standard one (nCPAP), the concept of the number needed to treat (NNT) is often used. Comparing MAD and nCPAP, the NNT is 7. This means that when 7 patients are treated in both groups, the nCPAP would treat 7 out of these 7 patients successfully and MAD only 6. In the worst-case scenario of the intention-to-treat analysis, the NNT is 6; in the best-case scenario it is 26. A NNT of 5 or more is usually interpreted as being an indication that there is no clinically relevant difference between the two treatments being compared [32]. This indicates that the non-significant difference between the MAD and nCPAP is not clinically relevant.

The placebo appliance also resulted in a small but significant reduction in the AHI. This observed reduction in the AHI may be due to a change in life style as the result of the information given to the patients at baseline, or it may be related to a placebo response. The AHI responses to the placebo treatment indicate that these factors may also play a role in the improvements seen in the MAD and nCPAP groups.

The results of the secondary respiratory variables indicate that the MAD and nCPAP are especially effective in the supine position. A part of this finding corresponds with the previous findings of Marklund et al [33], who found that successful reduction of the overall AHI with an MAD is related to the higher number of apnea/hypopneas in supine position. In the supine position, the nCPAP is effective in both sleep stages (REM and NREM), while the MAD shows no reduction compared to placebo in the REM sleep. During REM sleep, there is a reduction in activity of the pharyngeal musculature [34] and the positive airway pressure of nCPAP may be better capable of preventing a collapse of the upper airway during this reduced activity than the MAD.

Within the placebo group, an improvement in excessive daytime sleepiness could be observed. Therefore, it cannot be excluded that the improvement in ESS, observed in the pooled data of the MAD and nCPAP group, and also reported in other studies [7, 10, 24, 35] is unrelated to the mechanisms of the treatments (advancement of the mandible or the application of positive airway pressure) but is merely the result of a placebo effect, inevitably associated with these treatments, or due to a change in life style. The same may be true for the changes found in the domains of the short-form General Health Survey, SF-36 [20].

The relatively high compliance rates of approx. 90% (i.e., the percentage of nights per week usage) for the three therapies are
probably related to the frequent visits the patients paid to ACTA (once every four weeks) for interviews about, amongst others, the frequency of wearing. This regular contact with the examiner has probably motivated the patients to use their device on an almost nightly basis. The compliance rates in daily practice are probably lower and may also be different between MAD and nCPAP.

Snoring is one of the most frequently reported complaints of OSA patients, and in most cases the primary reason to seek help. However, it is seldom reported in OSA studies [6, 8, 10, 11]. This is probably due to difficulties in measuring this condition [36, 37]. In this study, snoring was evaluated at therapy evaluation by interviewing the patient. This approach has limitations in its dependency upon a bed partners’ report about the snoring habit of the patient. The present study suggests that both the MAD and the nCPAP treatment had a favourable influence upon the snoring of the patient.

Most of the side-effects reported by the MAD patients were mild, and did not differ from those reported previously [5, 36]. In the nCPAP group, three patients dropped out of the study, because they experienced more side-effects than benefits of the treatment. This suggests that nCPAP patients may show more problems in accepting their treatment modality than MAD patients.

Within the limits of this study, it can be concluded that the results do not point to a clinically relevant difference between MAD and nCPAP in the treatment of mild/ moderate OSA. Placebo effects probably play a role in the subjective treatment results.

Acknowledgements

The authors thank the staff of the Center for Sleep-Wake Disorders of Slotervaart Medical Center in Amsterdam, The Netherlands, for their assistance with this work; Dr. Corine Visscher and Dr. Irene Aartman for their assistance with the statistical analyses of this study; and Dental Laboratory Excent, Amsterdam, The Netherlands, for the assistance in the development of the MAD used in this study. The Netherlands Institute for Dental Sciences (IOT) supported this work.

Declarations of interest

No actual or potential conflicts of interest exist for any of the authors, nor is there any personal or financial support and author involvement with organizations with financial interest in the subject matter of the paper to be disclosed for any of the authors.
References


